BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

PURPOSE: The influence of the transcriptional and immunologic context of mutations on therapeutic outcomes with targeted therapy in cancer has not been well defined. BRAF V600E-mutant (BM) colorectal cancer comprises two main transcriptional subtypes, BM1 and BM2. We sought to determine the impact o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Middleton, Gary, Yang, Yiqun, Campbell, Catarina D., André, Thierry, Atreya, Chloe E., Schellens, Jan H.M., Yoshino, Takayuki, Bendell, Johanna C., Hollebecque, Antoine, McRee, Autumn J., Siena, Salvatore, Gordon, Michael S., Tabernero, Josep, Yaeger, Rona, O’Dwyer, Peter J., De Vos, Filip, Van Cutsem, Eric, Millholland, John M., Brase, Jan C., Rangwala, Fatima, Gasal, Eduard, Corcoran, Ryan B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8194012/
https://ncbi.nlm.nih.gov/pubmed/32047001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3579
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados